LENVIMA® (lenvatinib) is used by itself to treat differentiated thyroid cancer (DTC), a type of thyroid cancer that can no longer be treated with radioactive iodine and is progressing.
*Taken in combination with pembrolizumab.
†Taken in combination with everolimus after one course of treatment with another anti-cancer medicine.
You’re not in this
LENVIMA was studied in a clinical trial of 392 people with
DTC that had progressed and could no longer be treated
with radioactive iodine (RAI).
Financial assistance programs are available to help appropriate patients access LENVIMA.
Talk to your health care team to find out how you
will receive LENVIMA.